KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Equity Average (2016 - 2026)

Palvella Therapeutics has reported Equity Average over the past 9 years, most recently at $48.9 million for Q2 2022.

  • Quarterly Equity Average rose 15.13% to $48.9 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $48.9 million through Jun 2022, up 15.13% year-over-year, with the annual reading at -$21.5 million for FY2022, 152.61% down from the prior year.
  • Equity Average was $48.9 million for Q2 2022 at Palvella Therapeutics, down from $52.1 million in the prior quarter.
  • Over five years, Equity Average peaked at $53.0 million in Q2 2018 and troughed at $20.1 million in Q3 2019.
  • The 5-year median for Equity Average is $45.1 million (2018), against an average of $42.2 million.
  • Year-over-year, Equity Average soared 659.97% in 2018 and then plummeted 61.99% in 2019.
  • A 5-year view of Equity Average shows it stood at $45.1 million in 2018, then dropped by 20.18% to $36.0 million in 2019, then increased by 3.78% to $37.4 million in 2020, then skyrocketed by 40.0% to $52.3 million in 2021, then dropped by 6.49% to $48.9 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Equity Average are $48.9 million (Q2 2022), $52.1 million (Q1 2022), and $52.3 million (Q4 2021).